# US 2012/0259007 A1 · Anticoagulant compounds and their use

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2012/0259007 A1
- Document ID: US20120259007A1
- Status: Published application
- Kind: A1
- Application number: 13/518,618
- Filed: 2010-12-22
- Published: 2012-10-11
- Earliest claimed: 2009-12-23
- Assignees: Haoma Medica Limited
- Inventors: Stephen Hodges; Robin Soper
- Web page: https://patentgrep.com/patent/US20120259007A1

## CPC

- A61K 31/122: having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
- A61K 31/192: having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid {(cannabinoids A61K31/658)}
- A61K 31/216: of acids having aromatic rings, e.g. benactizyne, clofibrate
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 7/02: Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A61P 7/04: Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

According to the invention there is provided a compound of formula (I): wherein R1, R2, R3 and n have meanings given in the description, or a pharmaceutically acceptable solvate, salt or prodrug thereof for use as an anticoagulant.

## Claims

### Claim 1

A compound of formula (I):
wherein:
R1 represents hydrogen, halogen, cyano, trifluoromethyl, nitro, —ORa, SRa, SORa, —SO2Ra, —SO2NRaRb, —NRaRb, —NRaCORb, —NRaCO2Rb, —CORa, —CO2R1, —CONRaRb, or a hydrocarbon group comprising a straight chain, branched or cyclic group each containing up to 18 carbon atoms, or a heterocyclic group containing up to 18 carbon atoms and at least one heteroatom;
R2 represents, independently at each occurrence, hydrogen, halogen, cyano, trifluoromethyl, nitro, —ORa, SRa, SORa, —SO2Ra, —SO2NRaRb, —NRaCORb, —NRaCO2Rb, —CORa, —CO2Ra, —CONRaRb, or a hydrocarbon group comprising a straight chain, branched or cyclic group each containing up to 18 carbon atoms, or a heterocyclic group containing up to 18 carbon atoms and at least one heteroatom;
R3 represents a hydrocarbon group comprising a straight chained, branched or cyclic group each containing up to 18 carbon atoms, and being substituted by at least one moiety including a —CO2Ra substituent;
wherein Ra and Rb independently represent, at each occurrence, hydrogen, or a hydrocarbon group comprising a straight chained, branched or cyclic group each containing up to 18 carbon atoms, or a heterocyclic group containing up to 18 carbon atoms and at least one heteroatom; and
n is 0,1, 2, 3 or 4;
or a pharmaceutically acceptable solvate or, more particularly, salt or prodrug thereof;
for use as an anticoagulant.

### Claim 2 (depends on 1)

The compound for use according to claim 1, wherein:
R1 or R2 represents hydrogen, halogen, cyano, trifluoromethyl, nitro, —ORa, SRa, SORa, —SO2Ra, —SO2NRaRb, —NRaRb, —NRaCORb, —NRaCO2Rb, —CORa, —CO2Ra, —CONRaRb, or a hydrocarbon group comprising a straight chain, branched or cyclic group each containing up to 18 carbon atoms, or a heterocyclic group containing up to 18 carbon atoms and at least one heteroatom;
R3 represents a hydrocarbon group comprising a straight chained, branched or cyclic group each containing up to 18 carbon atoms, and being substituted by at least one moiety including a —CO2Ra substituent;
wherein Ra and Rb independently represent hydrogen, or a hydrocarbon group comprising a straight chained, branched or cyclic group each containing up to 18 carbon atoms, or a heterocyclic group containing up to 18 carbon atoms and at least one heteroatom;
n is 1, 2, 3 or 4.

### Claim 3 (depends on 1)

The compound for use according to claim 1, wherein: R1 represents a hydrocarbon group comprising a straight chain, branched or cyclic group each containing up to 18 carbon atoms.

### Claim 4 (depends on 2)

The compound for use according to claim 2, wherein R1 represents an alkyl group including straight chained or branched alkyl groups containing from 1 to 9 carbon atoms.

### Claim 5 (depends on 3)

The compound for use according to claim 3, wherein R1 represents methyl.

### Claim 6 (depends on 1)

The compound for use according to claim 1, wherein n represents 0.

### Claim 7 (depends on 2)

The compound for use according to claim 2, wherein n represents 4 and R2, at each occurrence, is hydrogen.

### Claim 8 (depends on 1)

The compound for use according to claim 1, wherein R3 represents a hydrocarbon group comprising a straight chained or branched hydrocarbon group containing up to 18 carbon atoms substituted by at least one moiety including a—CO2Ra substituent.

### Claim 9 (depends on 8)

The compound for use according to claim 8, wherein R3 represents C1-9 alkyl or C2-9 alkenyl, which groups can be straight chained or branched, substituted by at least one moiety including a —CO2Ra substituent.

### Claim 10 (depends on 9)

The compound for use according to claim 9, wherein Ra of the at least one moiety including a —CO2Ra substituent represents hydrogen or a hydrocarbon group comprising a straight chained or branched hydrocarbon group containing up to 18 carbon atoms.

### Claim 11 (depends on 10)

The compound for use according to claim 10, wherein Ra of the at least one moiety including a —CO2Ra substituent represents hydrogen or a hydrocarbon group comprising a straight chained or methyl.

### Claim 12 (depends on 8)

The compound for use according to claim 8, wherein R3 is represented by the following formula (II):
where the unattached bond represents the point of attachment of the structural fragment of formula (II) to the rest of the compound of Formula (I);
Ra is as defined in any preceding claim;
Rc, Rd and Re are independently selected from hydrogen or C1-6 alkyl (which can be straight chained or branched);
q is 1, 2, 3 or 4;
r and s are independently selected from 0, 1, 2, 3 or 4;
represents a single or double bond, and when this is a double bond Re is not present in above formula (II).

### Claim 13 (depends on 12)

The compound for use according to claim 12, wherein the structural fragment of formula (II) is selected from:
—(CH2)7CO2H;
—CH2CH═C(CH3)(CH2)2CO2H; and
—CH2CH═C(CH3)CO2H.

### Claim 14 (depends on 1)

The compound for use according to claim 1, wherein the compound of formula (I) is selected from the list comprising:
(i) 2,3-dimethoxy-1,4-naphthoquinone (XVI);
(ii) menadione (III);
(iii) KCAT-5C-Me (XIX);
(v) NaQuinate-Me (VII); more particularly,
(v) (4E)-6-(1,4-dihydro-2-methyl-1,4-dioxonaphthalcn-3-yl)-4-methylhex-4-enoic acid (VIII);
(vi) (2E)-4-(1,4-dihydro-2-methyl-1,4-dioxonaphthalen-3-yl)-2-methylbut-2-enoic acid (XIV); and
(vii) 8-(1,4-dihydro-2-methyl-1,4-dioxonaphthalen-3-yl)octanoic acid (XV).

### Claim 15 (depends on 14)

The compound for use according to claim 14, wherein the compound of formula (I) is selected from the list comprising:
(a) (4E)-6-(1,4-dihydro -2-methyl-1,4-dioxonaphthalen-3-yl)-4-methylhex-4-enoic acid (VIII);
(b) (2E)-4-(1,4-dihydro -2-methyl-1,4-dioxonaphthalen-3-yl)-2-methylbut-2-enoic acid (XIV); and
(c) 8-(1,4-dihydro-2-methyl-1,4-dioxonaphthalen-3-yl)octanoic acid (XV).

### Claim 16 (depends on 15)

The compound for use according to claim 15, wherein the compound of formula (I) is (4E)-6-(1,4-dihydro-2-methyl-1,4-dioxonaphthalen-3-yl)-4-methylhex-4-enoic acid (VIII).

### Claim 17 (depends on 1)

A pharmaceutical composition comprising a compound of formula (I) as defined in claim 1 and a pharmaceutically acceptable carrier, diluent or excipient therefor, for use as an anticoagulant.

### Claim 18 (depends on 1)

Use of a compound of formula (I) as defined in claim 1, in the manufacture of a medicament for use as an anticoagulant.

### Claim 19 (depends on 1, 17)

A method of treatment or prevention of a disorder or condition benefitting from anticoagulant therapy, which method comprises the administration of an effective amount of a compound of formula (I) as defined in claim 1, or a pharmaceutical composition as defined in claim 17, to a patient in need of such treatment.

### Claim 20 (depends on 1, 17)

A compound of formula (I) as defined in claim 1, or a pharmaceutical composition as defined in claim 17, for use in the prevention of thrombosis, or diseases caused thereby, in a patient who is to undertake a surgical procedure.

### Claim at position 21

-27. (canceled)

### Claim 28 (depends on 17)

The pharmaceutical composition as defined in claim 17, for use in modulating the coagulation effect of a coagulant.

### Claim 29 (depends on 1)

A coagulant for use in modulating the anticoagulation effect of a compound of formula (I) as defined in claim 1.

### Claim 30 (depends on 1)

A compound of formula (I) as defined in claim 1, for use in a method for the management of the blood clotting capability of a patient, the method comprising administering to a patient in need of treatment a therapeutically effective amount of the compound or composition to exert an anticoagulant effect, then administration of a coagulant to modulate or reverse the anticoagulant effect.

### Claim 31 (depends on 30)

The compound of claim 30, wherein the coagulant is vitamin K.

### Claim 32 (depends on 1)

A compound of formula (I) as defined in claim 1, for use in a treatment regime comprising treatment of a patient with the compound composition (I), then treatment of the same patient with vitamin K, or other coagulant, following surgery, to allow for blood clotting to occur.

### Claim 33

(canceled)

### Claim 34 (depends on 1)

A method for the treatment or prevention of diseases caused by blood coagulation, which comprises administering to a patient in need of treatment a therapeutically effective amount of a compound of claim 1.

### Claim 35 (depends on 1)

The compound of claim 1, wherein the compound of formula (I) is not vitamin K3.
